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ABSTRACT 
There is no single-component excipient fulfills all the requisite performance to allow an active pharmaceutical ingredient to be formulated into a 
specific dosage form. Co-processed excipient has received much more attention in the formulation development of various dosage forms, specially 
for tablet preparation by direct compression method. The objective of this review is to discuss the emergence of co-processed excipients as a 
current and future trend of excipient technology in pharmaceutical manufacturing. Co-processing is a novel concept of combining two or more 
excipients that possess specific advantages that cannot be achieved using a physical admixture of the same combination of excipients. This review 
article discusses the advantages of co-processing, the need of co-processed excipient, general steps in developing co-processed excipient, limitation 
of co-processed excipient, technologies used in developing co-processing excipients, co-processed excipients in the literature, marketed products 
and future trends. With advantages offered by the upcoming newer combination of excipients and newer methods of co-processing, co-processed 
excipients are for sure going to gain attraction both from academia and pharmaceutical industry. Furthermore, it opens the opportunity for 
development and use of single multifunctional excipient rather than multiple excipients in the formulation.  
Keywords: Orally disintegrating tablet, Oral drug delivery, Co-processed excipient, Direct compression 




In the past 10 y, the focus of both academia and pharmaceutical 
industry has been shifted from developing new active 
pharmaceutical ingredient (API) to formulation technology [1]. 
Pharmaceutical excipients have played a major role in that shift. 
Pharmaceutical excipients are defined as the substances other than 
the API which has been appropriately evaluated for safety and are 
intentionally included in a drug delivery system [2]. The 
International Pharmaceutical Excipients Council (2009) defines 
excipients as the substances which present in a finished 
pharmaceutical dosage form other than the active drug substance 
[3]. Excipient can be classified into four categories generally: single 
entity excipient, a physical blend of multiple excipients, new 
chemical entity excipient and co-processed excipient [4]. 
It is generally agreed by the formulation scientist that there is no 
single-component excipient fulfills all the requisite performance to 
allow an active pharmaceutical ingredient to be formulated into a 
specific dosage form [5]. On the other hand, developing a new 
chemical entity excipient requires a huge sum of investment [6]. To 
counter this issue, formulation scientist has introduced a novel 
concept of co-processing which is combining of two or more 
excipients that possess significant advantages that cannot be 
achieved using a physical admixture of the same combination of 
excipients [7]. A co-processed excipient is a combination of two or 
more compendial or non-compendial excipients designed to modify 
their physical properties in a manner not achievable by simple 
physical mixing, and without significant chemical change [2]. By 
formulating few excipients into a single composite material with 
specialized manufacturing method leads to an improvement in 
functionality of the end product [8]. This has become a newer trend 
in formulation development [9]. 
Co-processed excipient has received much more attention in the 
formulation development of various dosage forms such as a tablet, 
capsule, powder, cream, ointment, and others [10]. It is different 
from the physical mixture. Physical mixture is just a simple 
admixture combining few excipients by short duration shear 
processing. However, in the case of co-processed excipients, they 
possess performance advantages that cannot be achieved using a 
physical admixture of the same combination of excipients [11]. 
Combination of economical excipient with others of optimal quantity 
of a functional material will produce an integrated product with 
superior functionality than the simple mixture of components [12]. 
Co-processing generally does not involve chemical change. The 
changes in functionality are often contributed by the change in 
physical properties of the excipient particles [13].  
Oral delivery remains the most popular route of drug delivery [14]. 
It is because the oral drug delivery system has the key advantage of 
convenient drug administration. Tablets and hard gelatin capsules 
constitute a major portion of drug delivery systems that are 
currently available due to its convenience of self-administration, 
compactness and simple manufacturing process [15, 16]. Moreover, 
the drug is found to be more stable in solid dosage form than liquid 
dosage form [17]. 
The most common methods to manufacture tablets are wet 
granulation, dry granulation and direct compression [18]. If the 
major components of a formulation have already possessed good 
fluidity and compressibility, granulation would be redundant. Direct 
compression was reported as one of the most preferred methods 
due to some advantages such as time-saving, ease of production due 
to few steps involved, the absence of heat and moisture in the 
process [19]. In the survey by Shangraw and Damarest (1993), it 
was shown that direct compression was the most preferred tablet 
manufacturing method compared to wet granulation and roller 
compaction. About 41% of the companies indicated that direct 
compression was the method of choice, and 41.1% indicated that 
they used both direct compression and wet granulation. Only 1.7% 
of the respondents indicated that they never used direct 
compression and 15.5% indicated that the process was not 
recommended [19].  
A further advantage of direct compression is that tablets disintegrate 
into the primary particles bypassing granular aggregation stage. As a 
result, the effective surface area increases and dissolution of the drug 
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become faster [20]. However, the method encounters drawbacks due 
to lack of suitable excipients for direct compression application. Two 
major factors of powder characteristic which will critically affect the 
process of direct compression are compressibility and flowability [21, 
22]. The majority of the excipients that are currently available fail to 
meet the desired set of functionalities. It creates urgency for the 
development of high functionality excipients [23]. Therefore, the co-
processed excipient can play a role here to fill the gap of technology in 
direct compression. 
The aim of this article was to perform a literature review on co-
processed excipient and compile as well as discussing the co-
processed excipients available in the market and in literature. A 
detail literature review was conducted by searching keywords such 
as: a co-processed excipient, orally disintegrating tablet, oral drug 
delivery, tablet, direct compression, formulation, solid dosage form 
and powder. The search was done in the search engines including 
Science Direct, Science and Technology of Advanced Materials, PLOS 
ONE, Directory of Open Access Journals, CiteSeer and Google Scholar. 
Advantages of co-processing  
Improved compressibility 
Compressibility is an important factor of consideration in tablet 
development. Ideally, a compacted tablet is formed once the 
compression force is removed (6). However, all the conventional tablet 
excipients lack this plastic property. Majority of the co-processed 
adjuvants overcome this limitation. Flores et al. (2000) reported that the 
compressibility of Ludipress®, a co-processed adjuvant, is superior than 
the physical mixtures of their constituent excipients [24, 25]. 
Better dilution potential 
Dilution potential is defined as the ability of the excipient to retain its 
compressibility even when diluted with another low compressibility 
material. API and many inactive excipients have poor compressibility. On 
the other hand, a co-processed excipient with high dilution potential is 
desirous so that the compressibility properties of the mixture of powder 
blend can be maintained even when diluted with other excipients [26]. 
Cellactose® is shown to have a higher dilution potential than the 
physical mixture of its constituent excipients [27]. 
Reduced lubricant sensitivity 
Generally, hydrophobic lubricant provides a negative impact on the 
compression behavior of powder blend. Plasticity contributes brittle 
characteristic to an excipient. The presence of a large degree of 
brittle character in a co-processed excipient provides low lubricant 
sensitivity because it prevents the formation of a coherent lubricant 
network by forming newly exposed surfaces upon compression, thus 
breaking up the lubricant network [6].  
Ease of production 
Co-processed excipient simplifies the tablet formulation and 
development steps. Tablet formulation normally consists of 
weighing of active ingredient and various excipients followed by 
mixing, granulation, drying, sieving, and compression. Weighing of 
each ingredient might be time-consuming, and it may incur error in 
the process. Use of co-processed excipient might simplify the 
production process and reduces the rate of error [28]. 
Improved flow properties 
The co-processed excipient is reported to have better flow 
properties compared to its individual constituent or physical 
mixture by controlling the particle size distribution [29]. Good 
flowability is desired especially in case of high-speed rotary tablet 
machine [6]. The co-processing excipients play an important role in 
improving flow property of the powder mass ready for compression. 
A study showed that the co-processed Cellactose® has better flow 
than cellulose and lactose due to the spray drying technique used 
which resulted in particles of spherical shape and even surfaces [30].  
Fast disintegration 
Fast disintegration is compendial and formulation requirement for 
immediate release and orally disintegrating dosage form [31]. Co-
processed adjuvants, by virtue of their high solubility, swelling and 
wicking property, provide rapid disintegration to the developed 
formulation.  
Stability 
The co-processed excipient should be stable physically and chemically 
[6]. The ingredients used should be inert and not interact with the API. 
Cost saving 
The manufacturer uses a single excipient with multiple functional 
properties, thereby reducing the number of excipients used and 
labor cost involved in their processing other than direct 
compression method. Use of co-processed adjuvants simplifies 
manufacturing process which leads to time and cost saving.  
Need of co-processed excipients 
A list of available co-processed excipients is provided in table 1. However, 
they are not sufficient considering the diverse need of the 
pharmaceutical industries, specially for preparation of ODT tablets. 
There are only a few excipients are suitable for direct compression 
application. Most of the excipients having drawbacks such as lack of 
compressibility, poor flowability, lack of cohesion properties or 
lubrication [32]. As a result, a blend of few ingredients is required to 
achieve satisfactory condition prior to direct compression [33]. 
Moreover, the advance in tableting machinery has resulted in high-speed 
tablet machine with short duel times. Operation of this machine requires 
excipients with good compressibility flow property [4]. 
The role of co-processing comes into the picture by interacting two 
or more excipients at the sub-particle level, aimed at providing a 
synergy of functionality improvements, as well as masking the 
undesirable properties of the individual excipients [2]. The 
advancement and maturation of co-processing technology explore 
the possibility to produce tailor-made “designer excipients” to cater 
to various specific needs required for formulation development [32].  
General steps in developing co-processed excipients 
In order to design a new co-processed excipient which meets the 
functionality requirement of a specific application, few steps are 
important to take into consideration.  
a. Identification of the group of excipients to be co-processed 
A good co-processed excipient should look into the balance between 
plasticity and brittleness of a material [34]. Combination of plastic 
and brittle material nullifies storage of undesirable elastic energy 
during the compression. This will produce a product with a small 
amount of stress relaxation and a reduced tendency of capping and 
lamination thereby optimum tableting performance [35]. The 
combination of excipient chosen should complement each other and 
provide synergistic effect to achieve the desirable characteristics [6].  
b. Assessing the particle size 
Particle size will affect the compressibility and flowability of the end 
product. If the participating excipients have variation in initial 
particle sizes, the focus should be given to produce the final co-
processed adjuvant with uniform particle size. 
c. Selecting a suitable technique to co-process various excipient 
There are many methods which can be used for co-processing such 
as wet granulation, melt granulation, freeze drying, spray drying, hot 
melt extrusion [36-39]. A comprehensive detail has been provided 
later in this review. 
d. Optimizing the process and the proportion of each excipient 
This can contribute to functionality variations in the end product. 
Various optimization techniques and experimental designs with 
sound statistical analysis can be employed to obtain a final product 
with desired functionalities. 
Limitation of co-processed excipient 
Although co-processed excipient shows a list of promising benefits, 
however, there are few drawbacks in using of co-processed 
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adjuvants. Co-processed adjuvant is available as pre-mixed at a fixed 
ratio of an individual constituent. The user has no freedom to 
alternate the ratio of the excipient [40]. Moreover, co-processed 
adjuvant lacks the official acceptance in pharmacopeia [41]. For this 
reason, a co-processed adjuvant is not accepted by the 
pharmaceutical industry unless it exhibits significant advantages in 
the tablet compaction when compared to the physical mixtures of 
the excipients [2]. 
Technologies used in the manufacturing of co-processed 
excipients roller compaction 
Roller compaction uses the principle of dry granulation for particle 
bonding. This method is useful for ingredients which are sensitive to 
moisture and heat. The powder blend is mixed uniformly and 
compressed between counter-rotating rollers to form a ribbon of 
compacted material that is then milled into granules of appropriate 
particle size [42-44]. 
Wet granulation 
Wet granulation is a conventional and simple method for co-
processed adjuvant production. Fluid bed granulators and high-
shear mixers are two commonly used equipment used for the same. 
In fluid bed granulation, the powder mix is subjected to fluidization 
by a flow of air injected upwards through the bottom screen of the 
granulator. The binding solution is sprayed in the opposite direction 
to the air flow on the powder bed. The solid particles are mixed with 
the liquid droplets and hit the bed which results in adhesion and 
eventually the formation of granules. Partial drying by the fluidizing 
air occurs continuously during granulation [45-47]. 
In high-shear granulation, an impeller maintains the powder in 
agitation in a closed vessel. The binder solution is sprayed from the 
top. Development of large agglomerates is prevented by high shear 
force. With the new single-pot technology, drying occurs in the same 
system. The granules formed are understandably denser than those 
obtained in fluid bed granulation [48]. 
Hot melt extrusion 
Hot melt extrusion uses heat with a temperature greater than 80 °C. 
This method is not suitable for thermo labile materials. The 
excipients are melted and then pressurized through the die and 
solidify into a variety of shapes. The solvent is not required in the 
process as the molten polymer can function as a thermal binder [49]. 
Spray drying 
Spray drying generally involves five steps: Concentration of 
feedstock, atomization, droplet-air contact, droplet drying and 
separation and collection [50-51]. The technique transforms a feed 
which might be a solution, suspension or dispersion into dried 
particulate form by spraying it into a hot drying medium. The 
particle-particle bonding of excipients occurs during the process. 
The increased droplet surface area and high temperature cause the 
formation of spherical shape particles with improved flowability and 
suitable direct compression application such as Starlac®
Roller drying 
. 
A roller dryer is used to dry the homogeneous solution or dispersion 
containing the pre-blended excipients. Meggelaars et al. (1996) 
applied this technique to co-process lactose with sorbitol and lactitol 
[52]. The temperature used was sufficiently high to obtain an end 
product that consists principally of β-lactose in crystalline form.  
Co-transformation 
Co-transformation technique involves the application of heat or 
solvent effect to “open-up” (swelling) the particle of one excipient. 
The other excipients are incorporated into the “opened-up” 
structure of the aforementioned excipient. The augmented excipient 
strengthens the functionality of the end product [53, 54].  
Milling 
A roller mill, ball bill, bead mill, millstone mill, jet mill or a hammer mill 
can be used to perform milling or dry grinding. The excipients are 
premixed and passed through a high-speed milling machine. During 
the process of milling, the particles come in contact with each other 
and form bonds when they are subjected to force to mill or pass 
through the screen. Rao et al. (2012) applied this technique to co-
process cross-linked polyvinylpyrrolidone and calcium silicate [55].  
Melt granulation 
The blend of excipients are mixed with a meltable binder (normally 
at solid state below 80˚C). The mixture is subjected to heat above the 
melting point of the binder with continuous blending in order to 
break the mass into agglomerates. The cooled agglomerates are 
finally screened to obtain granules with desired size [56-57].  
Solvent evaporation 
Solvent evaporation takes place in a liquid manufacturing vehicle. 
The coating excipient is dissolved in a volatile solvent which is 
immiscible with the liquid manufacturing vehicle, followed by 
dissolving or dispersing the core excipient in the coating solution. 
Agitation force is applied to achieve the desired encapsulation size. 
Heat is used to evaporate the solvent [4].  
Co-processed excipient in the literature  
Microcrystalline cellulose (MCC) and calcium carbonate 
Mehra et al. (1986) patented a co-processed excipient of 
microcrystalline cellulose and calcium carbonate. The co-processed 
excipient was used to produce a directly compressed vitamin tablet. 
The invention was economical and exhibited low lubricant 
sensitivity [58].  
Lactose, polyvinylpyrrolidone (PVP) and crospovidone 
Lang (1991) reported a blend of lactose, PVP and crospovidone 
which was produced through spray drying, spray granulation or wet 
granulation method. The novel direct tableting auxiliaries exhibited 
good flow, good compressibility under low pressure, excellent 
disintegration properties coupled with great hardness and low 
abrasion [59]. 
β-lactose and sorbitol 
Meggelaars et al. (1996) prepared a homogeneous mass consisting 
of a dried solution of high β-lactose content with sorbitol ranges 
from 1-15% % w/w. Roller drying technique was used in the drying 
process. The excipient can be used to prepare tablet with exclusive 
hardness [52]. 
Cornstarch and polyvinylpyrrolidone 
Menon et al. (1996) described a co-processed excipient consisting of 
cornstarch and polyvinylpyrrolidone produced using fluid bed spray 
granulation method. The invention is free-flowing and exhibits good 
compressibility [60]. 
Colloidal silicon dioxide and MCC 
Sherwood et al. (1996) patented a novel MCC-colloidal silicon 
dioxide excipient that was found to be free flowing, possess excellent 
disintegration properties and have improved compressibility 
relative to normal “off the shelf” commercially available MCC [61]. 
Guar gum and MCC 
Ratnaraj and Reilly (1997) produced a co-processed excipient for 
the chewable tablet by thoroughly mixing an aqueous dispersion of 
MCC and guar gum under high shear conditions at room 
temperature. The homogenous dispersion was then spray dried to 
an aggregate powder having substantially spheroidal-shaped 
particles. The excipient has improved compressibility and mouth 
feel. It reduces tooth packing [62]. 
Directly compressible sucrose 
The invention contains 95% sucrose and 5% of maltodextrin. This 
sugar-based excipient is free-flowing, compressible and has a 
pleasant taste and mouthfeel which can be helpful in masking the 
bitter taste of API [63].  
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MCC and methylcellulose 
Augello and Vladyka (1999) invented a co-processed excipient by 
wet granulating MCC and methylcellulose. The compositions were 
then subjected to spheronizing into spheres having a smooth 
uniform surface. The end product serves as a coating polymer 
which provides complete taste masking of a bitter drug such as 
ibuprofen while having no adverse impact on the bioavailability of 
the drug [64]. 
MCC and sodium alginate 
The invention is a wet granulation binder type excipient by Augello 
and Reier (1999). A uniform aqueous slurry of MCC and sodium 
alginate was formed firstly, followed by drying the slurry to granular 
particular [65].  
Alfalfa, MCC and calcium carbonate 
Ibrahim and Saraiya (2001) developed a co-processed excipient 
comprised of alfalfa root, MCC and calcium carbonate. Spray dried 
procedure was used in the development process. The said product 
was applied to formulate vitamin and nutritional supplements [66].  
MCC and maltodextrin 
Buliga et al. (2002) blended MCC and maltodextrin and sprayed 
dried the dispersion. The invention was reported to mix with 
carboxymethyl cellulose to produce a dry blend that can be used in 
food and cosmetic application as stabilizer [67].  
Rice starch and MCC 
Limwong et al. (2004) invented a co-processed excipient comprising 
of rice starch and MCC. Composite particles of rice starch and MCC 
were fabricated by spray-drying technique to be used as a directly 
compressible excipient. The compressibility was greater than 
commercial spray-dried rice starch (Eratab), coprocessed lactose 
and microcrystalline cellulose (Cellactose), and agglomerated 
lactose (Tablettose), but, lower than microcrystalline cellulose 
(Vivapur 101) [36]. 
Calcium phosphate and fatty acid wax 
Cucula et al. (2006) produced a co-processed excipient containing 
calcium phosphate and fatty acid wax (glyceryl behenate or glyceryl 
palmitostearate) using melt granulation method. Co-processing of 
calcium phosphate with fatty acid wax overcomes the abrasiveness 
and capping issues normally associated with calcium phosphate. It 
was applied to formulate venlafaxine HCL modified release tablet, 
and venlafaxine besylate extended-release tablet [68].  
Sorbitol and mannitol 
Norman et al. (2006) reported a blend of sorbitol and mannitol 
prepared by dissolving mannitol powder and sorbitol powder into a 
solution. The solution was then dried in an air stream and forming a 
composition that completely dissolves in the oral cavity within 60 
seconds. The invention is suitable for orally disintegrating tablet 
application [69].  
Crospovidone and sodium starch glycolate 
Gohel et al. (2007) developed the co-processed excipient through 
wet granulation and tray drying technique. Blend of crospovidone 
and sodium starch glycolate was added to isopropyl alcohol for wet 
granulation. The wet mass was sieved and dried in a tray dryer. The 
end product exhibited good flow property, compaction and 
disintegration property. The invention was applied as a 
superdisintegrant in the formulation of cefiximetri hydrate and 
ibuprofen tablet [37].  
Copolymer of vinylpyrrolidone (VP) and vinyl acetate (VA) and 
MCC 
Halder et al. (2007) developed a co-processed adjuvant containing a 
copolymer of vinylpyrrolidone, vinyl acetate and MCC. This 
synergistic binder composition was applied to produce tablets with 
exclusive hardness and acceptable friability. It is suitable to be used 
in tablet formulation containing poorly compressible drug [70]. 
MCC and mannitol 
Slurry of MCC and mannitol were sprayed dried to spherical 
particulate. The composition had an improved compatibility profile, 
lubricant sensitivity, and ejection profile compared to the physical 
mixture and individual component [71]. 
Mannitol and calcium silicate 
A co-processed excipient which is suitable for orally disintegrating 
tablet application was developed by Gandhi et al. (2009). Mannitol 
was dispersed in water followed by dispersing calcium silicate in the 
solution. The mixture was spray dried to granules. The tablet 
produced by compression of the excipient disintegrated in less than 
60 seconds [72].  
Crospovidone and croscarmellose sodium 
Nagendrakumar et al. (2009) blended croscarmellose sodium and 
crospovidone in ethanol. The mixture was stirred until most of the 
ethanol evaporated. The wet coherent mass was sieved and dried in 
a hot air oven. The invention serves as a co-processed 
superdisintegrant. It was applied to formulate granisetron fast 
dissolving tablet [73]. 
Mannitol and cellulose 
Patel SS and Patel NM (2007) prepared a co-processed excipient of 
mannitol and cellulose for dispersible tablet application. The end 
product was prepared using the freeze-thawing method and was 
claimed to have an improvement in flowability, compatibility and 
dissolution rate of a model drug [9]. 
Povidone and glyceryl behenate 
Ayyappan et al. (2010) developed a co-processed adjuvant 
comprising povidone and glyceryl behenate which was claimed to 
function as binder and lubricant with good flow and compressibility. 
The co-processed excipient was applied to manufacture tramadol 
HCl control release tablet and it provided a drug release profile 
comparable with Zydol SR [74].  
Microcrystalline and spray dried lactose 
Dey et al. (2010) produced co-processed excipient of various ratio 
combination of microcrystalline cellulose, spray dried lactose and 
pearlitol. The study concluded that co-processed excipient of 
microcrystalline and spray dried lactose at 90:10 % w/w was the 
optimum formulation which showed good compressibility and fast 
disintegration. The product was applied to formulate paracetamol 
orally disintegrating tablet [75].  
Sodium carbonate and polyethylene glycol 
The invention is a pH modifier developed by Davar et al. (2010) 
using a fluid bed spray granulation method. Polyethylene glycol 
protects sodium carbonate from moisture which results in caking. 
The said invention was applied in the non-effervescent 
pharmaceutical composition of zolpidem and scopolamine [76].  
Starch and magnesium silicate 
Adnan et al. (2011) co-processed starch with magnesium silicate. 
Starch was suspended in a suspension first followed by addition of 
magnesium silicate. The suspension was then filtered, washed and 
dried. The dried product was used to prepare tablets with high 
mechanical strength, short disintegration time and low lubricant 
sensitivity [77]. 
Lactose, MCC and cornstarch 
Akram et al. (2011) developed co-processed micro-granules of 
lactose monohydrate, MCC and cornstarch by wet granulation. The 
finished product was claimed to have the strong binding ability, fast 
disintegration time and improved flow property [78]. 
α-chitin and mannitol 
Al Omari et al. (2011) published research on the development of α-
chitin and mannitol co-processed excipient by fluid bed spray 
granulation method. The invention was applied in the orally 
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disintegrating tablet to contribute to exclusive hardness, low 
friability, low ejection force while retaining rapid disintegration 
properties [79]. 
Dibasic calcium phosphate, HPMC and crospovidone 
Deorkar et al. (2011) formulated an invention by co-processing 
dibasic calcium phosphate as a brittle material component, HPMC as 
binder and crospovidone as a disintegrant. The invention showed an 
increased flowability, API loading, and blendability and higher 
compatibility [80]. 
MCC and HPMC 
Deorkar et al. (2011) prepared a co-processed excipient by spray 
dry granulating an aqueous slurry comprised of the microcrystalline 
cellulose and HPMC. Then invention has enhanced flowability, high 
compatibility, and increased API loading and 
The co-processed excipient was reported by Gangurde and Amin (2013) 
using roller compaction method. Polyox WSR-301 and HPMC K4M 
powder samples were forced between two counter-rotating rolls and 
screened through 60 mesh sieve. The obtained fine powder was further 
recycled to get granules of uniform size. The finished product was 
applied to produce metformin HCl sustained release tablet [83]. 
blendability as 
compared to the individual components [80]. 
Maize starch and acacia 
Olowosulu et al. (2011) developed co-processed excipient of maize 
and acacia by co-drying or a well dispersed aqueous mixture of the 
two. The drying was performed on a water bath system at 50̊ C and 
80˚C for 15 min with constant stirring respectively to compare the 
effect of partial and fully gelatinization. The fully gelatinized form 
showed good flowability but poor crushing strength. In contrast, the 
tablets produced by partially gelatinized form showed good crushing 
strength and friability profile [81].  
Calcium phosphate and MCC 
Thoorens et al. (2011) invented a calcium phosphate and MCC co-
processed excipient by mixing the aqueous slurries of 
microcrystalline cellulose and calcium phosphate, followed by 
drying such slurries to produce particulate products. The end 
product exhibited improved compatibility, as compared to dry 
physical blends of the same components [82]. 
Polyox WSR-301 and HPMC K4M 
Dicalcium phosphate and carboxymethylcellulose sodium 
Ambore et al. (2014) studied on various ratio combination of 
dicalcium phosphate and carboxymethylcellulose co-processed 
using co-precipitation method. The study concluded that the flow 
property of the co-processed excipient improves significantly 
compared to the physical mixture. The excipient had good dilution 
potential and was used to produce a tablet with poorly compressible 
drugs such as paracetamol and ibuprofen [29].  
Dicalcium phosphate and carboxymethylcellulose sodium 
The invention was developed by Ambore et al. (2014) using co-
precipitation technique. Carboxymethylcellulose was dispersed in 
water to allow it to swell. Dicalcium phosphate was dispersed in 
another portion of water. The two portions of dispersion were 
mixed and dried in tray dried. The invention was reported to have 
better flowability and dilution potential [29].  
Chitosan and Eudragit S-100 
Pawar et al. (2014) prepared a co-processed excipient of chitosan 
and Eudragit S-100 using the solvent evaporation method. The co-
processed excipient was applied to produce venlafaxine HCl 
sustained release tablet via direct compression [84].  
Lentinus tuber regium base co-processed excipient 
Ugoeze and Nkoro (2015) developed a co-processed excipient by 
mixing Lentinus tuber regium, sodium bicarbonate, tartaric acid and 
citric acid using solvent evaporation method. The end product 
appears as a compactable, tasteless, off-white powder without 
distinct odor. The flow property, compressibility, and dilution 
potential were improved [12]. 
Marketed products 
There are many marketed products of co-processed excipients 
available. The marketed products are presented in table 1. 
  
Table 1: Products of co-processed excipients which are available in the market 
Trade name Excipients Manufacturer Added advantage Reference 
Ludipress  Lactose, kallidon 30, kallidon CL BASF Low degree of 
hydroscopicity, good 
flowability, tablet hardness 
independent of machine 
speed 
85 
Cellactose  Lactose and cellulose Meggle High compressibility, good 
mouth feel, better tableting 
at low cost 
86 
Dipac Sucrose and dextrin Penwest Pharm Directly compressible grade 87 
Prosolv Microcrystalline cellulose and silicon 
dioxide 
Penwest Pharmaceuticals Better flow, reduced 
sensitivity to wet 
granulation, better hardness 
of tablet, reduced friability 
88 
Avicel ce-15  Microcrystalline cellulose and guar 
gum 
FMC Corp. Less grittiness and minimal 
chalkiness 
89 
Formaxx  Calcium carbonate and sorbitol Merck High compressibility, 
excellent taste masking, free 
flow, superior content 
uniformity, controlled 
particle size distribution 
90 
Microcelac  Microcrystalline cellulose and lactose Meggle Capable of formulating high 
dose, small tablets with 
poorly flowable active 
ingredients 
91 
Starlac  Lactose and maize starch Meggle Good flowability due to 
spray drying, the acceptable 
crushing force due to lactose 
content and rapid 
disintegration depending on 
56 
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Pharmatose DCL 40  β-lactose and anhydrous lactitol  DFE Pharma Spherical shape particle with 
good flowability, good 
binding property and not 
hygroscopic  
92 
Starch 1500  Amylose, amylopectin, and starch  Colorcon It is a directly compressible, 
free-flowing, USP grade of 
partially hydrolyzed 
cornstarch. The tablets 
produced disintegrates very 
fast 
93 
Pearlitol SD  Granulated mannitol  Roquette  Suitable for chewable tablet 
application with good 
mouthfeel and palatability 
73 
Advantose FS-95  Fructose and starch SPI Polyols Good mouthfeel and fast 
disintegration property. 
Suitable for nutraceuticals 
and chewable vitamin 
applications 
90 
Finlac DC  Directly compressible lactitol Cultor Food Science Direct compression grade. 
Good mouthfeel and fast 
disintegration property. 
Suitable for nutraceuticals 
and chewable vitamin 
applications 
94 
Plasdone S-630 Vinyl acetate and vinyl pyrolidone ISP Good roller compaction 
binder, improved hardness 
and better drug dissolution 
profile  
24 
Lycatab C  Pregelatinized starch Roquette Suitable for moisture 
sensitive API. 
95 
Copovidone  Kollidon VA 64 and plasdone S630 Ashland Excellent flow properties 
and dry binder 
24 
Ludiflash  Mannitol, crospovidone and polyvinyl 
acetate 
BASF Suitable for high-speed 
tableting, low friability, and 
good flowability 
41 
Orocell 200 and Orocell 
400  
Spheronized mannitol Pharmatrans Sanaq Filler-binder with high 
dilution potential and good 
disintegrating property 
41 
Cel-O-Cal  Microcrystalline cellulose and 
calcium sulphate 
FMC Biopolymer Directly compressible binder 41 
Tablettose  Spray dried lactose (agglomerated 
form) 
Meggle Good flowability and direct 
compressible 
96 
Xylitab  Xylitol and sodium 
carboxymethylcellulose 
Danisco Directly compressible and 
good palatability 
97 
StarCap 1500  Maize starch and pregel starch Colorcon Tablet disintegration and 
dissolution independent of 
pH 
98 
Vitacel VE-650  Microcrystalline cellulose and 
calcium carbonate 




LustreClear  Microcrystalline cellulose and 
carrageenan 
FMC Biopolymer Efficient Tablet coating with 
short hydration time prior to 
coating and the first drying 
time 
2 
Pharmaburst  Carbohydrate system, made from 
compendia ingredients 
SPI Pharma High compatibility, high 
loading in, small tablets, 
smooth mouth, feel, rapid, 
disintegration 
99 
Effersoda Sodium bicarbonate and sodium 
carbonate  
SPI Pharma Improve the stability of the 
Effervescent product 
2 
Sorbcel M  Mannitol, polyethylene glycol, 
polyvinylpyrrolidone, citric acid and 
sodium bicarbonate 
Blanver Effervescent excipients, 
Homogeneous and stable 
mix of excipients that 
dissolves completely and 
rapidly, resulting in a 
clear solution free of 
insoluble residues 
2 
Sorbcel E  Sorbitol, mannitol,  
polyvinylpyrrolidone, citric acid and 
sodium bicarbonate 
Blanver Effervescent excipients, 
A homogeneous and stable 
mix of excipients 
that dissolves completely 
and rapidly, resulting in a 
clear solution free of  
2 
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Fujicalin  DCP anhydrous Fuji Chemicals Directly compressible, 




Neusilin  Amorphous magnesium 
aluminometasilicate 
Fuji Chemicals Improve flow, anti-caking, 
improve Compressibility and 
to make solid dispersion 
101 
F-Melt  Carbohydrate, disintegrant and DCP Fuji Chemicals Directly Compressible, oral 
Disintegrating time less than 
30 seconds, highly flowable 
with minimum or no 
sticking/capping 
51 
Sepitrap 80  Polysorbate 80 Seppic Improves the bioavailability 
of APIs with low solubility. It 
can be used in direct 
compression processes 
95 
Sepitrap 4000  Ethoxylated 
hydrogenated castor 
oil 
Seppic Improves the bioavailability 
of APIs with low solubility. It 
can be used in direct 
compression processes 
95 





Traditional inert excipients with lack of desired functionalities have 
drawn the attention of pharmaceutical formulator in developing new 
co-processed adjuvants. The recent developments in the field of 
excipients, advancement in high-speed manufacturing machinery 
and novel co-processing techniques have further added driving force 
for the growth of this field. An exploration of solid-state properties 
of excipients and its impact on functionality is further going to fuel 
this trend. Moreover, increase cost in developing new chemical 
entity and an increasing preference for the direct compaction 
process create a significant opportunity for the development of high-
functionality co-processed excipients. It is predicted that the 
development of tailor-made designed excipients complying with 
safety, performance, and regulatory issues is a current and future 
trend in excipient technology [95]. With advantages offered by the 
upcoming newer combination of excipients and newer methods of 
co-processing, co-processed excipients are for sure going to gain 
attraction both from academia and pharmaceutical industry [102]. 
Furthermore, it opens the opportunity for development and use of 
single multifunctional excipients rather than multiple excipients in 
formulation [103]. 
CONCLUSION  
The co-processed excipients play a pivotal role in formulating 
stable, result oriented drug delivery system with an improved 
physical, chemical and mechanical properties [104]. Furthermore, 
co-processed excipients solve the issues of precompression 
parameters, compressibility, palatability, disintegration, 
dissolution, and sticking which conventional individual excipients 
might have. Co-processed excipient is a promising tool in 
pharmaceutical excipient development [105]. The existing co-
processed adjuvants cannot fulfill all the functionalities required 
for preparation of various novel formulations. Cost is another 
factor that incurs increased the price of the final product. So, there 
is enough scope of development of new co-processed excipients to 
meet the demand of pharmaceutical industries. It is expected that 
advanced research in academia and pharmaceutical industry will 
surely bridge this gap in the near future.  
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